1
|
Ashraf AR, Mackey TK, Vida RG, Kulcsár G, Schmidt J, Balázs O, Domián BM, Li J, Csákó I, Fittler A. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res 2024; 26:e65440. [PMID: 39509151 PMCID: PMC11582493 DOI: 10.2196/65440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2024] [Revised: 09/18/2024] [Accepted: 09/19/2024] [Indexed: 11/15/2024] Open
Abstract
BACKGROUND Over the past 4 decades, obesity has escalated into a global epidemic, with its worldwide prevalence nearly tripling. Pharmacological treatments have evolved with the recent development of glucagon-like peptide 1 agonists, such as semaglutide. However, off-label use of drugs such as Ozempic for cosmetic weight loss has surged in popularity, raising concerns about potential misuse and the emergence of substandard and falsified products in the unregulated supply chain. OBJECTIVE This study aims to conduct a multifactor investigation of product quality and patient safety risks associated with the unregulated online sale of semaglutide by examining product availability and vendor characteristics and assessing product quality through test purchases. METHODS We used a complex risk and quality assessment methodology combining online market surveillance, search engine results page analysis, website content assessment, domain traffic analytics, conducting targeted product test purchases, visual quality inspection of product packaging, microbiological sterility and endotoxin contamination evaluation, and quantitative sample analysis using liquid chromatography coupled with mass spectrometry. RESULTS We collected and evaluated 1080 links from search engine results pages and identified 317 (29.35%) links belonging to online pharmacies, of which 183 (57.7%) led to legal pharmacies and 134 (42.3%) directed users to 59 unique illegal online pharmacy websites. Web traffic data for the period between July and September 2023 revealed that the top 30 domains directly or indirectly affiliated with illegal online pharmacies accumulated over 4.7 million visits. Test purchases were completed from 6 illegal online pharmacies with the highest number of links offering semaglutide products for sale without prescription at the lowest price range. Three injection vial purchases were delivered; none of the 3 Ozempic prefilled injection pens were received due to nondelivery e-commerce scams. All purchased vials were considered probable substandard and falsified products, as visual inspection indicated noncompliance in more than half (59%-63%) of the evaluated criteria. The semaglutide content of samples substantially exceeded labeled amounts by 28.56%-38.69%, although no peptide-like impurities were identified. The lyophilized peptide samples were devoid of viable microorganisms at the time of testing; however, endotoxin was detected in all samples with levels ranging between 2.1645 EU/mg and 8.9511 EU/mg. Furthermore, the measured semaglutide purity was significantly low, ranging between 7.7% and 14.37% and deviating from the 99% claimed on product labels by manufacturers. CONCLUSIONS Glucagon-like peptide 1 agonist drugs promoted for weight loss, similar to erectile dysfunction medications more than 2 decades ago, are becoming the new blockbuster lifestyle medications for the illegal online pharmacy market. Protecting the pharmaceutical supply chain from substandard and falsified weight loss products and raising awareness regarding online medication safety must be a public health priority for regulators and technology platforms alike.
Collapse
Affiliation(s)
- Amir Reza Ashraf
- Department of Pharmaceutics, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
| | - Tim Ken Mackey
- Global Health Program, Department of Anthropology, University of California San Diego, La Jolla, CA, United States
| | - Róbert György Vida
- Department of Pharmaceutics, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
| | - Győző Kulcsár
- Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
| | - János Schmidt
- Institute of Biochemistry and Medical Chemistry, Medical School, University of Pécs, Pécs, Hungary
| | - Orsolya Balázs
- Department of Pharmaceutics, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
| | - Bálint Márk Domián
- Department of Pharmaceutics, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
| | - Jiawei Li
- S-3 Research, San Diego, CA, United States
| | - Ibolya Csákó
- Criminal Department, Criminal Directorate, Hungarian National Police Headquarters, Budapest, Hungary
| | - András Fittler
- Department of Pharmaceutics, Faculty of Pharmacy, University of Pécs, Pécs, Hungary
| |
Collapse
|
2
|
Deville M, Charlier C. Barbie drug identification: Not a child's play. J Forensic Sci 2024; 69:2331-2338. [PMID: 39302005 DOI: 10.1111/1556-4029.15633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2024] [Revised: 08/25/2024] [Accepted: 09/09/2024] [Indexed: 09/22/2024]
Abstract
Various samples-including two vials with a pharmaceutical appearance-were submitted to the laboratory for identification. The aim of this work was to describe the unique characteristics observed during the analysis of the powder contained in the vial. Samples were submitted to HPLC-DAD, UHPLC-TOF-MS, and/or UPLC-MS-MS analysis. The majority of the samples were easily identified as standard drugs of abuse. The main difficulty lay in identifying the powder in the vials. No match was found in the library through HPLC-DAD analysis. Fortunately, the vials were labeled as "Melanotan II", although the UV spectrum was not available. Mass spectrometric analysis of melanotan II was challenging, as it is a small peptide with a molecular weight of 1024 Da, which is significantly heavier than classical drugs that the laboratory usually handles. As a result, mass spectrometer's parameters can be limited to detect masses up to 1000 Da. Additionally, melanotan II is multi-charged which is also unusual for compounds typically targeted in our daily work. Finally, the reference standard allowed us to confirm the identification with both instruments, and determine the purity of 30%. Melanotan II is not approved on the market due to safety concerns. It is used illegally mainly for tanning, explaining its nickname "Barbie drug". To conclude, analysis of melanotan II was challenging as it is heavy and doubly charged. Moreover, its UV spectrum was initially not available in the literature. The difficulties faced by forensic scientists in detecting this drug may explain its popularity on the illicit market.
Collapse
Affiliation(s)
- Marine Deville
- Laboratory of Clinical, Forensic and Environmental Toxicology, Center for Interdisciplinary Research on Medicines (CIRM), University Hospital of Liege, Liège, Belgium
| | - Corinne Charlier
- Laboratory of Clinical, Forensic and Environmental Toxicology, Center for Interdisciplinary Research on Medicines (CIRM), University Hospital of Liege, Liège, Belgium
| |
Collapse
|
3
|
Harwacki J, Pisklak DM, Szeleszczuk L. Solid state 13C NMR spectroscopy as a tool for identification of counterfeit Viagra tablets and guide for develop new identification approach of falsified product. Int J Pharm 2023; 636:122837. [PMID: 36921742 DOI: 10.1016/j.ijpharm.2023.122837] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Revised: 03/03/2023] [Accepted: 03/10/2023] [Indexed: 03/16/2023]
Abstract
Counterfeit drugs are a global problem that is directly related to the safety and effectiveness of pharmacotherapy. The black market for counterfeit products is constantly growing and related to the wide availability through online shopping. Therefore, there is a constant need to develop analytical methods that would allow for the unambiguous identification of counterfeit products from the original ones. One of such techniques is solid-state NMR spectroscopy, which allows for direct registration and analysis of spectra of multicomponent solid forms of pharmaceutical formulations. The paper explores the possibility of using this technique in the identification of counterfeit Viagra tablets. In this study, solid-state NMR has been used to detect the non-pharmacopoeial cellulose present in the samples of counterfeit Viagra tablets. Besides, the NMR results allowed to develop a rapid dying technique that can be used to distinguish between the counterfeit and original drug. It has been shown that solid-state NMR spectroscopy allows for numerous analyses such as identification of counterfeit products, assessment of the composition of analyte, estimation of qualitative differences between the original and falsified product, and the development of simple analytical methods based on tablets composition differences.
Collapse
Affiliation(s)
- Jakub Harwacki
- Medical University of Warsaw, Faculty of Pharmacy, Department of Organic and Physical Chemistry, Stefana Banacha 1, 02-097 Warsaw, Poland.
| | - Dariusz Maciej Pisklak
- Medical University of Warsaw, Faculty of Pharmacy, Department of Organic and Physical Chemistry, Stefana Banacha 1, 02-097 Warsaw, Poland.
| | - Lukasz Szeleszczuk
- Medical University of Warsaw, Faculty of Pharmacy, Department of Organic and Physical Chemistry, Stefana Banacha 1, 02-097 Warsaw, Poland.
| |
Collapse
|
4
|
ALSaeedy M, Al-Adhreai A, Öncü-Kaya EM, Şener E. An Overview of Advances in the Chromatography of Drugs Impurity Profiling. Crit Rev Anal Chem 2022; 53:1455-1471. [PMID: 35180027 DOI: 10.1080/10408347.2022.2032587] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/23/2023]
Abstract
A systematic literature survey published in several journals of pharmaceutical chemistry and of chromatography used to analyze impurities for most of the drugs that have been reviewed. This article covers the period from 2016 to 2020, in which almost of chromatographic techniques have been used for drug impurity analysis. These chromatography techniques are important in the analysis and description of drug impurities. Moreover, some recent developments in forced impurity profiling have been discussed, such as buffer solutions, mobile phase, columns, elution modes, and detectors are highlighted in drugs used for the study. This primarily focuses on thorough updating of different analytical methods which include hyphenated techniques for detecting and quantifying impurity and degradation levels in various pharmaceutical matrices.
Collapse
Affiliation(s)
- Mohammed ALSaeedy
- Department of Chemistry, Faculty of Applied Sciences, Dhamar University, Dhamar, Yemen
- Department of Analytical Chemistry, Faculty of Sciences, Eskisehir Technical University, Eskisehir, Turkey
| | - Arwa Al-Adhreai
- Department of Chemistry, Faculty of Applied Sciences, Dhamar University, Dhamar, Yemen
- Department of Chemistry, Maulana Azad of Arts, Science and Commerce, Aurangabad, India
| | - Elif Mine Öncü-Kaya
- Department of Analytical Chemistry, Faculty of Sciences, Eskisehir Technical University, Eskisehir, Turkey
| | - Erol Şener
- Department of Analytical Chemistry, Faculty of Pharmacy, Anadolu University, Eskisehir, Turkey
| |
Collapse
|
5
|
Legrand P, Dembele O, Alamil H, Lamoureux C, Mignet N, Houzé P, Gahoual R. Structural identification and absolute quantification of monoclonal antibodies in suspected counterfeits using capillary electrophoresis and liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2022; 414:2699-2712. [PMID: 35099584 PMCID: PMC8802745 DOI: 10.1007/s00216-022-03913-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2021] [Revised: 01/09/2022] [Accepted: 01/18/2022] [Indexed: 11/29/2022]
Abstract
Monoclonal antibodies (mAbs) represent a major category of biopharmaceutical products which due to their success as therapeutics have recently experienced the emergence of mAbs originating from different types of trafficking. We report the development of an analytical strategy which enables the structural identification of mAbs in addition to comprehensive characterization and quantification in samples in potentially counterfeit samples. The strategy is based on the concomitant use of capillary zone electrophoresis analysis (CZE-UV), size exclusion chromatography coupled to multi-angle light scattering (SEC-MALS) and liquid chromatography hyphenated to tandem mass spectrometry (LC-MS/MS). This analytical strategy was applied to the investigation of different samples having unknown origins seized by the authorities, and potentially incorporating an IgG 4 or an IgG 1. The results achieved from the different techniques demonstrated to provide orthogonal and complementary information regarding the nature and the structure of the different mAbs. Therefore, they allowed to conclude unequivocally on the identification of the mAbs in the potentially counterfeit samples. Finally, a LC-MS/MS quantification method was developed which specificity was to incorporate a different mAbs labeled with stable isotopes as internal standard. The LC-MS/MS quantification method was validated and thus demonstrated the possibility to use common peptides with the considered IgG in order to achieve limit of quantification as low as 41.4 nM. The quantification method was used to estimate the concentration in the investigated samples using a single type of internal standard and experimental conditions, even in the case of mAbs with no stable isotope labeled homologues available.
Collapse
Affiliation(s)
- Pauline Legrand
- Faculté de Sciences Pharmaceutiques et Biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1022, Université de Paris, Paris, France.,Département Recherche Et Développement Pharmaceutique, Agence Générale Des Equipements Et Produits de Santé (AGEPS), Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Oumar Dembele
- Faculté de Sciences Pharmaceutiques et Biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1022, Université de Paris, Paris, France
| | - Héléna Alamil
- Faculté de Sciences Pharmaceutiques et Biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1022, Université de Paris, Paris, France
| | - Catherine Lamoureux
- Service Commun de Laboratoire DGCCRF-DGCCI (SCL), Laboratoire de Paris, Massy, France
| | - Nathalie Mignet
- Faculté de Sciences Pharmaceutiques et Biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1022, Université de Paris, Paris, France
| | - Pascal Houzé
- Faculté de Sciences Pharmaceutiques et Biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1022, Université de Paris, Paris, France.,Laboratoire de Toxicologie Biologique, Hôpital Lariboisière, Assistance Publique - Hôpitaux de Paris (AP-HP), Paris, France
| | - Rabah Gahoual
- Faculté de Sciences Pharmaceutiques et Biologiques, Unité de Technologies Chimiques et Biologiques pour la Santé (UTCBS), CNRS UMR8258, Inserm U1022, Université de Paris, Paris, France. .,Unité de Technologies Biologiques Et Chimiques Pour La Santé (UTCBS), Faculté de Pharmacie, Université Paris Descartes, 4, avenue de l'observatoire, 75270, Cedex 06, Paris, France.
| |
Collapse
|
6
|
Deconinck E, Vanhee C, Keizers P, Guinot P, Mihailova A, Syversen PV, Li-Ship G, Young S, Blazewicz A, Poplawska M, Al-Sayed JL, Stengelshøj Olsen L, El-Atma O, Leist R, Jönsson KH, Afxentiou M, Barrios MM, Diaz ID, Zemser M, Kozokin A, Hackl A, Portela MJ, Beerbaum N, Bertrand M. The occurrence of non-anatomical therapeutic chemical-international nonproprietary name molecules in suspected illegal or illegally traded health products in Europe: A retrospective and prospective study. Drug Test Anal 2021; 13:833-840. [PMID: 33453144 DOI: 10.1002/dta.3001] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Revised: 12/23/2020] [Accepted: 01/12/2021] [Indexed: 11/11/2022]
Abstract
The General European Official Medicines Control Laboratory (OMCL) Network (GEON), co-ordinated by the European Directorate for the Quality of Medicines & HealthCare (EDQM), regularly organises market surveillance studies on specific categories of suspected illegal or illegally traded products. These studies are generally based on a combination of retrospective and prospective data collection over a defined period of time. This paper reports the results of the most recent study in this context with the focus on health products containing non-Anatomical Therapeutic Chemical-International Nonproprietary Name (ATC-INN) molecules. In total 1104 cases were reported by 16 countries for the period between January 2017 and the end of September 2019. The vast majority of these samples (83%) were collected from the illegal market, while only 3% originated from a legal source. For the rest of the samples, categorisation was not possible. Moreover, 69% of all the reported samples were presented as medicines, including sexual performance enhancers, sports performance enhancers, physical performance enhancers and cognitive enhancers or nootropic molecules that act on the central nervous system (CNS). Although the popularity of anabolics, PDE-5 inhibitors and CNS drugs in illegal products has already been reported, the study showed some new trends and challenges. Indeed, 11% of the samples contained molecules of biological origin, that is, research peptides, representing the second most reported category in this study. Furthermore, the study also clearly shows the increasing popularity of Selective Androgen Receptor Modulators and nootropics, two categories that need attention and should be further monitored.
Collapse
Affiliation(s)
- Eric Deconinck
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, Brussels, Belgium
| | - Celine Vanhee
- Scientific Direction Chemical and Physical Health Risks, Service of Medicines and Health Products, Sciensano, Brussels, Belgium
| | - Peter Keizers
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Department of Product Composition, National Institute for Public Health and the Environment, Bilthoven, The Netherlands
| | - Pauline Guinot
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Laboratory Controls Division, French National Agency for Medicines and Health Products Safety, Vendargues, France
| | - Albena Mihailova
- Laboratory, Division Reliable Supply, Norwegian Medicines Agency, Oslo, Norway
| | - Per Vidar Syversen
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Laboratory, Division Reliable Supply, Norwegian Medicines Agency, Oslo, Norway
| | - Graziella Li-Ship
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Inspections, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, UK
| | - Steven Young
- Inspections, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency, London, UK
| | - Agata Blazewicz
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Falsified Medicines and medical Devices Department, National Medicines Institute, Warsaw, Poland
| | - Magdalena Poplawska
- Falsified Medicines and medical Devices Department, National Medicines Institute, Warsaw, Poland
| | | | - Lone Stengelshøj Olsen
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Medicines Control and Inspection Division, Danish Medicines Agency, Copenhagen, Denmark
| | - Oliver El-Atma
- Medicinal Products, Chemical and Veterinary Investigation Office, Karlsruhe, Germany
| | - Roman Leist
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,OMCL, Swissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland
| | - Karl-Henrik Jönsson
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Laboratory Department, Swedish Medical Products Agency, Uppsala, Sweden
| | - Maria Afxentiou
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Forensic Chemistry and Toxicology Laboratory, State General Laboratory, Nicosia, Cyprus
| | - M Mendoza Barrios
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Chemical and Pharmaceutical Division, Medicines for Human Use Department, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain
| | - I Dorronsoro Diaz
- Chemical and Pharmaceutical Division, Medicines for Human Use Department, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Madrid, Spain
| | - Marina Zemser
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Institute of Standardization and Control of Pharmaceuticals, Ministry of Health Israel, Jerusalem, Israel
| | - Alla Kozokin
- Institute of Standardization and Control of Pharmaceuticals, Ministry of Health Israel, Jerusalem, Israel
| | - Andreas Hackl
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Institute Assessment & Analytics, Analytics of chemical-pharmaceutical Medicinal Products, AGES-Österreichische Agentur für Gesundheit und Ernährungssicherheit GmbH, Wien, Austria
| | - Maria-Jao Portela
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France.,Direção de Comprovação da Qualidade, INFARMED-Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., Lisbon, Portugal
| | - Nico Beerbaum
- Institut für Lebensmittel, Arzneimittel, Tierseuchen und Umwelt, Landeslabor Berlin-Brandenburg, Berlin, Germany
| | - Marie Bertrand
- OMCL Falsified Medicines Working Group, GEON Network, EDQM-Council of Europe, Strasbourg, France
| |
Collapse
|
7
|
Zhang H, Hua D, Huang C, Samal SK, Xiong R, Sauvage F, Braeckmans K, Remaut K, De Smedt SC. Materials and Technologies to Combat Counterfeiting of Pharmaceuticals: Current and Future Problem Tackling. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2020; 32:e1905486. [PMID: 32009266 DOI: 10.1002/adma.201905486] [Citation(s) in RCA: 67] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 10/25/2019] [Indexed: 05/28/2023]
Abstract
The globalization of drug trade leads to the expansion of pharmaceutical counterfeiting. The immense threat of low quality drugs to millions of patients is considered to be an under-addressed global health challenge. Analytical authentication technologies are the most effective methods to identify active pharmaceutical ingredients and impurities. However, most of these analytical testing techniques are expensive and need skilled personnel. To combat counterfeiting of drugs, the package of an increasing number of drugs is being protected through advanced package labeling technologies. Though, package labeling is only effective if the drugs are not repackaged. Therefore "in-drug labeling," instead of "drug package labeling," may become powerful tools to protect drugs. This review aims to overview how advanced micro- and nanomaterials might become interesting markers for the labeling of tablets and capsules. Clearly, how well such identifiers can be integrated into "solid drugs" without compromising drug safety and efficacy remains a challenge. Also, incorporation of tags has so far only been reported for the protection of solid drug dosage forms. No doubts that in-drug labeling technologies for "liquid drugs," like injectables which contain expensive peptides, monoclonal antibodies, vaccines, dermal fillers, could help to protect them from counterfeiting as well.
Collapse
Affiliation(s)
- Heyang Zhang
- Joint Laboratory of Advanced Biomedical Technology (NFU-UGent), College of Chemical Engineering, Nanjing Forestry University, 210037, Nanjing, P. R. China
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000, Ghent, Belgium
| | - Dawei Hua
- Joint Laboratory of Advanced Biomedical Technology (NFU-UGent), College of Chemical Engineering, Nanjing Forestry University, 210037, Nanjing, P. R. China
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000, Ghent, Belgium
| | - Chaobo Huang
- Joint Laboratory of Advanced Biomedical Technology (NFU-UGent), College of Chemical Engineering, Nanjing Forestry University, 210037, Nanjing, P. R. China
| | - Sangram Keshari Samal
- Laboratory of Biomaterials and Regenerative Medicine for Advanced Therapies, Indian Council of Medical Research-Regional Medical Research Center, 751023, Bhubaneswar, India
| | - Ranhua Xiong
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000, Ghent, Belgium
| | - Félix Sauvage
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000, Ghent, Belgium
| | - Kevin Braeckmans
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000, Ghent, Belgium
| | - Katrien Remaut
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000, Ghent, Belgium
| | - Stefaan C De Smedt
- Joint Laboratory of Advanced Biomedical Technology (NFU-UGent), College of Chemical Engineering, Nanjing Forestry University, 210037, Nanjing, P. R. China
- Laboratory of General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, 9000, Ghent, Belgium
| |
Collapse
|
8
|
Vanhee C, Francotte A, Janvier S, Deconinck E. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind. Drug Test Anal 2020; 12:371-381. [DOI: 10.1002/dta.2717] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2019] [Revised: 10/10/2019] [Accepted: 10/11/2019] [Indexed: 01/17/2023]
Affiliation(s)
- Celine Vanhee
- Section Medicines and Health Products, Scientific Direction of Chemical and Physical Health Risks Sciensano Brussels Belgium
| | - Antoine Francotte
- Section Medicines and Health Products, Scientific Direction of Chemical and Physical Health Risks Sciensano Brussels Belgium
- Section Quality of Vaccines and Blood Products, Scientific Direction of Expertise and Service Provision Sciensano Brussels Belgium
| | - Steven Janvier
- Section Organic Contaminants and Additives, Scientific Direction of Chemical and Physical Health Risks Sciensano Brussels Belgium
| | - Eric Deconinck
- Section Medicines and Health Products, Scientific Direction of Chemical and Physical Health Risks Sciensano Brussels Belgium
| |
Collapse
|
9
|
dos Santos MK, de Cassia Mariotti K, Kahmann A, Anzanello MJ, Ferrão MF, de Araújo Gomes A, Limberger RP, Ortiz RS. Comparison between counterfeit and authentic medicines: A novel approach using differential scanning calorimetry and hierarchical cluster analysis. J Pharm Biomed Anal 2019; 166:304-309. [DOI: 10.1016/j.jpba.2019.01.029] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2018] [Revised: 01/14/2019] [Accepted: 01/16/2019] [Indexed: 01/31/2023]
|
10
|
Janvier S, De Spiegeleer B, Vanhee C, Deconinck E. Falsification of biotechnology drugs: current dangers and/or future disasters? J Pharm Biomed Anal 2018; 161:175-191. [DOI: 10.1016/j.jpba.2018.08.037] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 08/01/2018] [Accepted: 08/16/2018] [Indexed: 02/06/2023]
|